PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30514659-0 2019 Efficacy of early imaging with 68Ga-PSMA-I&T in the discrimination of pelvic lesions in prostate cancer patients. Adenosine Monophosphate 43-46 folate hydrolase 1 Homo sapiens 36-40 31529265-0 2020 68Ga-PSMA I&T PET/CT for primary staging of prostate cancer. Adenosine Monophosphate 12-15 folate hydrolase 1 Homo sapiens 5-9 31529265-1 2020 PURPOSE: The present study is based on a retrospective analysis of Gallium-68 (68Ga)-labelled prostate-specific membrane antigen (68Ga-PSMA I&T) PET/CT performed in newly diagnosed, treatment-naive prostate cancer (PCa) patients prior to definitive treatment. Adenosine Monophosphate 142-145 folate hydrolase 1 Homo sapiens 135-139 30237214-3 2019 Methods: The in vitro PSMA-targeting efficiency of PSMA-I&F, the reference PSMA-I&T, and their corresponding natGa-/68Ga- and natLu/177Lu counterparts was determined in LNCaP cells via competitive binding assays (IC50) and dual-tracer radioligand and fluorescence internalization studies. Adenosine Monophosphate 58-61 folate hydrolase 1 Homo sapiens 22-26 30237214-9 2019 Tumor-to-background ratios of 2.1, 5.2, 9.6, and 9.6 for blood, liver, intestines, and muscle, respectively, at 1 h after injection led to excellent imaging contrast in 68Ga-PSMA-I&F PET and in intraoperative fluorescence imaging. Adenosine Monophosphate 181-184 folate hydrolase 1 Homo sapiens 174-178 30237214-11 2019 Conclusion: Thus, with its high PSMA-targeting efficiency and favorable pharmacokinetic profile, 68Ga/177Lu-PSMA-I&F serves as an excellent proof-of-concept compound for the general feasibility of PSMA-I&T-based hybrid imaging. Adenosine Monophosphate 115-118 folate hydrolase 1 Homo sapiens 32-36 30237214-11 2019 Conclusion: Thus, with its high PSMA-targeting efficiency and favorable pharmacokinetic profile, 68Ga/177Lu-PSMA-I&F serves as an excellent proof-of-concept compound for the general feasibility of PSMA-I&T-based hybrid imaging. Adenosine Monophosphate 115-118 folate hydrolase 1 Homo sapiens 108-112 30237214-11 2019 Conclusion: Thus, with its high PSMA-targeting efficiency and favorable pharmacokinetic profile, 68Ga/177Lu-PSMA-I&F serves as an excellent proof-of-concept compound for the general feasibility of PSMA-I&T-based hybrid imaging. Adenosine Monophosphate 115-118 folate hydrolase 1 Homo sapiens 108-112 30237214-11 2019 Conclusion: Thus, with its high PSMA-targeting efficiency and favorable pharmacokinetic profile, 68Ga/177Lu-PSMA-I&F serves as an excellent proof-of-concept compound for the general feasibility of PSMA-I&T-based hybrid imaging. Adenosine Monophosphate 208-211 folate hydrolase 1 Homo sapiens 108-112 30237214-11 2019 Conclusion: Thus, with its high PSMA-targeting efficiency and favorable pharmacokinetic profile, 68Ga/177Lu-PSMA-I&F serves as an excellent proof-of-concept compound for the general feasibility of PSMA-I&T-based hybrid imaging. Adenosine Monophosphate 208-211 folate hydrolase 1 Homo sapiens 108-112 31069696-14 2019 CONCLUSION: In the present study, (68Ga)PSMA I&T was found to be quite successful in determining lesions in the biochemical recurrence, which is consistent with the findings of other I&T studies and studies conducted with different PSMA ligands. Adenosine Monophosphate 47-50 folate hydrolase 1 Homo sapiens 40-44 30514659-3 2019 In this study we planned to assess the significance of an additional early imaging in 68Ga-PSMA-I&T PET/CT imaging in prostate cancer patients. Adenosine Monophosphate 98-101 folate hydrolase 1 Homo sapiens 91-95 30514659-15 2019 CONCLUSION: Our study is the first in the literature to evaluate the impact of adding an early static pelvic image to the 68Ga-PSMA-I&T scan, in the detection rate of the lesions. Adenosine Monophosphate 134-137 folate hydrolase 1 Homo sapiens 127-131 30514659-16 2019 Although there was no marked discordance between the 2sets of images, the addition of an early image to the imaging protocol of 68Ga-PSMA-I&T scan would increase the efficacy of detection of malignant lesions in the pelvis, which might show rapid clearance and has the risk of being masked by the urinary system activity. Adenosine Monophosphate 140-143 folate hydrolase 1 Homo sapiens 133-137 30087939-3 2018 The specific binding toward human serum albumin (HSA) decreased from 78.6% for [natLu]PSMA I&T to 19.9% for the natLu-labeled cellobiose derivative. Adenosine Monophosphate 93-96 folate hydrolase 1 Homo sapiens 86-90 28474140-5 2017 In this study, we examine whether PSMA-I&T has comparative efficacy, such that it could replace PSMA-HBED as a diagnostic agent in prostate carcinoma. Adenosine Monophosphate 41-44 folate hydrolase 1 Homo sapiens 34-38 29324926-11 2017 PSMA PET/CT sensitivity, specificity, PPV and NPV for extra prostatic extension (EPE), seminal vesicle invasion (SVI) and lymphatic metastases were 63.16%, 100%, 100%, 36.36% & 55%, 100%, 100%, 25% and 65.62%, 99.31%, 87.50%, 97.53%, respectively. Adenosine Monophosphate 176-179 folate hydrolase 1 Homo sapiens 0-4 28301262-6 2017 In vivo, tumor uptake of 213Bi-PSMA I&T and 213Bi-JVZ-008 was 5.75% +- 2.70%ID/g (injected dose per gram) and 2.68% +- 0.56%ID/g, respectively, with similar tumor-to-kidney ratios. Adenosine Monophosphate 38-41 folate hydrolase 1 Homo sapiens 31-35 28511221-1 2017 Recently, the use of 111In-labeled PSMA-I&T-based radioguided surgery (111In-PSMA-RGS) for salvage surgery using intraoperative ex-vivo gamma-probe measurements has been described by our group as a promising new and individual treatment concept in patients with localised recurrent prostate cancer (PC). Adenosine Monophosphate 42-45 folate hydrolase 1 Homo sapiens 35-39 28511221-1 2017 Recently, the use of 111In-labeled PSMA-I&T-based radioguided surgery (111In-PSMA-RGS) for salvage surgery using intraoperative ex-vivo gamma-probe measurements has been described by our group as a promising new and individual treatment concept in patients with localised recurrent prostate cancer (PC). Adenosine Monophosphate 42-45 folate hydrolase 1 Homo sapiens 81-85 28301262-8 2017 213Bi-PSMA I&T induced significantly more DSBs than 213Bi-JVZ-008 (p < 0.01). Adenosine Monophosphate 13-16 folate hydrolase 1 Homo sapiens 6-10 27011373-0 2016 68Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging. Adenosine Monophosphate 12-15 folate hydrolase 1 Homo sapiens 5-9 27635024-6 2017 The pharmacokinetics of 99mTc-PSMA-I&S in humans were investigated in a patient with advanced metastatic PCa via sequential planar whole-body SPECT imaging at 1, 3, 5, and 21 h after injection. Adenosine Monophosphate 37-40 folate hydrolase 1 Homo sapiens 30-34 27635024-10 2017 Compared with 111In-PSMA-I&T, 99mTc-PSMA-I&S showed delayed clearance kinetics but identical uptake in PSMA-positive tissues in the LNCaP xenograft model (1 h after injection). Adenosine Monophosphate 47-50 folate hydrolase 1 Homo sapiens 40-44 27635024-10 2017 Compared with 111In-PSMA-I&T, 99mTc-PSMA-I&S showed delayed clearance kinetics but identical uptake in PSMA-positive tissues in the LNCaP xenograft model (1 h after injection). Adenosine Monophosphate 47-50 folate hydrolase 1 Homo sapiens 40-44 27635024-11 2017 In exemplary PCa patients, a relatively slow whole-body clearance of 99mTc-PSMA-I&S was observed due to high plasma protein binding (94%) of the tracer. Adenosine Monophosphate 82-85 folate hydrolase 1 Homo sapiens 75-79 27635024-13 2017 Preoperative SPECT/CT showed a high 99mTc-PSMA-I&S uptake in all suspect lesions identified in previous 68Ga-HBED-CC-Ahx-KuE (68Ga-HBED-CC-PSMA) PET/CT, allowing for their successful intraoperative detection and resection during first-in-human RGS. Adenosine Monophosphate 49-52 folate hydrolase 1 Homo sapiens 42-46 27635024-2 2017 To meet the clinical need for a more cost-effective alternative, the PSMA-I&T-based tracer concept was adapted to 99mTc-labeling chemistry. Adenosine Monophosphate 76-79 folate hydrolase 1 Homo sapiens 69-73 27885457-2 2017 Several PSMA ligands such as PSMA-617 or PSMA-I&T have been developed that can be labeled with beta-radiating lutetium-177. Adenosine Monophosphate 48-51 folate hydrolase 1 Homo sapiens 8-12 15153802-3 2004 In this issue of Cancer Biology & Therapy, a targeted approach to prostate cancer chemotherapy is explored using the inherent enzymatic activity of prostate-specific membrane antigen (PSMA) and peptide conjugated methotrexate. Adenosine Monophosphate 33-36 folate hydrolase 1 Homo sapiens 152-186 27276206-3 2016 Whole-body scintigraphy and SPECT/CT were performed 4 hours after application of 147.0 +- 24.8 MBq (range, 90-183 MBq) In-PSMA I&T. Images were evaluated for suspected lesions, and conspicuity of all lesions was rated using a 4-point-scale (0 = not seen, 1 = retrospectively seen in knowledge of Ga-PSMA HBED-CC PET, 2 = low signal, 3 = high signal). Adenosine Monophosphate 129-132 folate hydrolase 1 Homo sapiens 122-126 27276206-9 2016 CONCLUSIONS: In a preselected collective of recurrent prostate cancer patients with low PSA values, In-PSMA I&T SPECT/CT showed lower detection rates than hybrid Ga-HBED-CC PSMA PET. Adenosine Monophosphate 110-113 folate hydrolase 1 Homo sapiens 103-107 26089548-6 2015 RESULTS: PSMA I&T and its cold gallium and lutetium analog revealed nanomolar affinity toward PSMA. Adenosine Monophosphate 16-19 folate hydrolase 1 Homo sapiens 98-102 26089548-11 2015 Endoradiotherapy with (177)Lu-PSMA I&T in 2 patients was found to be effective and safe with no detectable side effects. Adenosine Monophosphate 37-40 folate hydrolase 1 Homo sapiens 30-34 25883128-2 2015 EuK-Subkff-(68)Ga-DOTAGA ((68)Ga-PSMA Imaging & Therapy [PSMA I&T]) is a recently introduced PET tracer for imaging PSMA expression in vivo. Adenosine Monophosphate 47-50 folate hydrolase 1 Homo sapiens 33-37 25883128-2 2015 EuK-Subkff-(68)Ga-DOTAGA ((68)Ga-PSMA Imaging & Therapy [PSMA I&T]) is a recently introduced PET tracer for imaging PSMA expression in vivo. Adenosine Monophosphate 47-50 folate hydrolase 1 Homo sapiens 61-65 25883128-2 2015 EuK-Subkff-(68)Ga-DOTAGA ((68)Ga-PSMA Imaging & Therapy [PSMA I&T]) is a recently introduced PET tracer for imaging PSMA expression in vivo. Adenosine Monophosphate 47-50 folate hydrolase 1 Homo sapiens 61-65 26964917-11 2016 CONCLUSIONS: Radioligand therapy with (177)Lu-PSMA-I&T appears to be safe and active in heavily pretreated patients with metastatic castration resistant prostate cancer. Adenosine Monophosphate 53-56 folate hydrolase 1 Homo sapiens 46-50 26608882-5 2015 revealed slightly reduced background accumulation of [(111)In]PSMA-I&T compared to [(177)Lu]PSMA-I&T and identical tumor uptake of both compounds, leading to increased tumor/background ratios for [(111)In]PSMA-I&T. An exemplary patient with metastatic PCa underwent preoperative [(68)Ga]HBED-CC-PSMA PET/CT (1 h p.i.) Adenosine Monophosphate 69-72 folate hydrolase 1 Homo sapiens 62-66 26608882-12 2015 In an exemplary PCa patient, [(111)In]PSMA-I&T was successfully applied for preoperative SPECT/CT visualization and radioguided resection of PSMA-positive lesions, hinting towards a high value of [(111)In]PSMA-I&T as a complementary tool to [(68)Ga/(177)Lu]PSMA-I&T in the clinical management of prostate cancer. Adenosine Monophosphate 45-48 folate hydrolase 1 Homo sapiens 38-42 26608882-12 2015 In an exemplary PCa patient, [(111)In]PSMA-I&T was successfully applied for preoperative SPECT/CT visualization and radioguided resection of PSMA-positive lesions, hinting towards a high value of [(111)In]PSMA-I&T as a complementary tool to [(68)Ga/(177)Lu]PSMA-I&T in the clinical management of prostate cancer. Adenosine Monophosphate 45-48 folate hydrolase 1 Homo sapiens 145-149 26608882-12 2015 In an exemplary PCa patient, [(111)In]PSMA-I&T was successfully applied for preoperative SPECT/CT visualization and radioguided resection of PSMA-positive lesions, hinting towards a high value of [(111)In]PSMA-I&T as a complementary tool to [(68)Ga/(177)Lu]PSMA-I&T in the clinical management of prostate cancer. Adenosine Monophosphate 45-48 folate hydrolase 1 Homo sapiens 145-149 26608882-12 2015 In an exemplary PCa patient, [(111)In]PSMA-I&T was successfully applied for preoperative SPECT/CT visualization and radioguided resection of PSMA-positive lesions, hinting towards a high value of [(111)In]PSMA-I&T as a complementary tool to [(68)Ga/(177)Lu]PSMA-I&T in the clinical management of prostate cancer. Adenosine Monophosphate 45-48 folate hydrolase 1 Homo sapiens 145-149 26608882-12 2015 In an exemplary PCa patient, [(111)In]PSMA-I&T was successfully applied for preoperative SPECT/CT visualization and radioguided resection of PSMA-positive lesions, hinting towards a high value of [(111)In]PSMA-I&T as a complementary tool to [(68)Ga/(177)Lu]PSMA-I&T in the clinical management of prostate cancer. Adenosine Monophosphate 216-219 folate hydrolase 1 Homo sapiens 38-42 26608882-12 2015 In an exemplary PCa patient, [(111)In]PSMA-I&T was successfully applied for preoperative SPECT/CT visualization and radioguided resection of PSMA-positive lesions, hinting towards a high value of [(111)In]PSMA-I&T as a complementary tool to [(68)Ga/(177)Lu]PSMA-I&T in the clinical management of prostate cancer. Adenosine Monophosphate 216-219 folate hydrolase 1 Homo sapiens 145-149 26608882-12 2015 In an exemplary PCa patient, [(111)In]PSMA-I&T was successfully applied for preoperative SPECT/CT visualization and radioguided resection of PSMA-positive lesions, hinting towards a high value of [(111)In]PSMA-I&T as a complementary tool to [(68)Ga/(177)Lu]PSMA-I&T in the clinical management of prostate cancer. Adenosine Monophosphate 216-219 folate hydrolase 1 Homo sapiens 145-149 26608882-12 2015 In an exemplary PCa patient, [(111)In]PSMA-I&T was successfully applied for preoperative SPECT/CT visualization and radioguided resection of PSMA-positive lesions, hinting towards a high value of [(111)In]PSMA-I&T as a complementary tool to [(68)Ga/(177)Lu]PSMA-I&T in the clinical management of prostate cancer. Adenosine Monophosphate 216-219 folate hydrolase 1 Homo sapiens 145-149 15153802-3 2004 In this issue of Cancer Biology & Therapy, a targeted approach to prostate cancer chemotherapy is explored using the inherent enzymatic activity of prostate-specific membrane antigen (PSMA) and peptide conjugated methotrexate. Adenosine Monophosphate 33-36 folate hydrolase 1 Homo sapiens 188-192